Translational Development Acquisition (TDACW) Non Operating Income (2024 - 2026)
Translational Development Acquisition's (TDACW) quarterly Non Operating Income came in at $1.6 million in Q2 2026, down 12.82% on a YoY basis from $1.8 million in Q2 2025, and little changed quarter-over-quarter from $1.6 million in Q1 2026.
Analysis
Translational Development Acquisition (TDACW) Non Operating Income (2024 - 2026) Analysis & Trends
Translational Development Acquisition (TDACW) has reported Non Operating Income for 3 consecutive years, with $1.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Income fell 12.82% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2026 stood at $6.9 million (up 80.35% YoY), and the FY2025 full-year result was $7.3 million, up 5729.44% from the prior year.
- Non Operating Income was little changed at $1.6 million in Q2 2026 per TDACW's latest filing, from $1.6 million in the prior quarter.
- Across five years, Non Operating Income topped out at $1.9 million in Q3 2025 and bottomed at $125346.0 in Q4 2024.
- Historically, Non Operating Income has averaged $1.5 million across 3 years, with a median of $1.8 million in 2025.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income jumped 1302.7% in 2025, then declined 12.82% in 2026.
- Over 3 years, Non Operating Income stood at $125346.0 in 2024, then surged by 1302.7% to $1.8 million in 2025, then slipped by 8.54% to $1.6 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $1.6 million, $1.6 million, and $1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Evercore | 11.52 Bn | 9.43 Bn | 975.67 Mn | - |
| 2 | Jefferies Financial | 11.24 Bn | -4.17 Bn | 3.09 Bn | - |
| 3 | Houlihan Lokey | 9.53 Bn | 8.45 Bn | - | - |
| 4 | Cluster Group Holdings | 8.00 Bn | 8.00 Bn | - | - |
| 5 | PJT Partners | 6.94 Bn | 6.99 Bn | 481.98 Mn | - |
| 6 | Moelis | 6.06 Bn | 5.99 Bn | - | 2.45 Mn |
| 7 | Piper Sandler Companies | 5.20 Bn | 5.09 Bn | - | 14.09 Mn |
| 8 | Lazard | 4.97 Bn | 3.99 Bn | - | - |
| 9 | BRBI BR Partners | 3.44 Bn | 3.32 Bn | 16.77 Mn | - |
| 10 | Translational Development Acquisition | 52.67 Mn | 52.58 Mn | - | 1.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Dec 31, 2024 | 125,346.00 |